Trial Profile
Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refractory Neuroblastoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2018
Price :
$35
*
At a glance
- Drugs Anti GD2 chimeric antigen receptor T cell therapy Bellicum Pharmaceuticals (Primary) ; Cyclophosphamide; Fludarabine
- Indications Neuroblastoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 02 Feb 2018 Status changed to recruiting.
- 05 Jan 2018 New trial record